RxDoctor Payments Data

John Sun, MD

Gastroenterology · Tacoma, WANPI 1972681500

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $184,675 of the $218,819 with a category attached, or 84.4%. AbbVie accounts for 100.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $79,891 and has fallen 81.4% since, to $14,827 in 2025. Among gastroenterology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$218,819in general payments, 2019–2025

Across 335 payments — averaging $653.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$219K
  • Olympus America Inc.$51
  • Stryker$44

What the payments were for

  • Speaking & faculty fees$184,67584%
  • Travel & lodging$26,57012%
  • Food & beverage$7,5533%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)332$218,724
Olympus America Inc.2$51
Stryker1$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$218,819 in reported general payments places this provider in the 95th percentile of 447 gastroenterology providers in Washington.

See all gastroenterology providers in Washington

Medicare billing

Part B allowed, 2024
$69,598
Medicare patients
280
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase29$53,635
LinzessLinaclotide24$12,935
Omeprazole174$3,006
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl112$1,808
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates23$1,440
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl91$1,433
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl48$791
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg27$462
Famotidine27$402
Pantoprazole Sodium38$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$218,724$66,56953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 447 gastroenterology providers in Washington.

Other gastroenterology in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →